论文部分内容阅读
[目的]研究慢性丙型肝炎(CHC)与丙型肝炎病毒/人类免疫缺陷病毒(HCV/HIV)共感染者用聚乙二醇干扰素α-2a(PEG-IFNα-2a)抗病毒治疗疗效的观察。[方法]治疗前后定期采集30例CHC(HCV组)、30例HCV/HBV共感染者的外周血,检测HCV RNA、血常规和肝功酶谱指标。[结果]治疗后HCV组的HCV-RNA阴转率(73.33%)和PLT(227.13±79.34)均高于共感染组(20%、177.73±66.05),ALT、AST及APRI评分分别为(57.90±24.67、61.60±25.27、0.80±0.54)均低于共感染组(77.90±30.20、76.33±28.60、1.20±0.58)。[结论]PEG-lFNα-2a抗病毒治疗HCV/HIV共感染者疗效较单纯丙型肝炎患者差,并且对造血系統的影响较大,建议有条件的患者应用直接抗病毒药物。
[Objective] To investigate the effect of peginterferon alfa-2a (PEG-IFNα-2a) antiviral therapy in patients with chronic hepatitis C (CHC) and hepatitis C virus / human immunodeficiency virus (HCV / HIV) Observation. [Methods] Peripheral blood samples of 30 CHC (HCV group) and 30 HCV / HBV co-infected patients were collected regularly before and after treatment. HCV RNA, blood routine and liver enzymes were detected. [Results] The HCV-RNA negative rates (73.33%) and PLT (227.13 ± 79.34) in HCV group were significantly higher than those in co-infected group (20%, 177.73 ± 66.05), and the ALT, AST and APRI scores were ± 24.67,61.60 ± 25.27,0.80 ± 0.54) were lower than the co-infected group (77.90 ± 30.20,76.33 ± 28.60,1.20 ± 0.58). [Conclusion] The efficacy of PEG-lFNa-2a antiviral treatment of HCV / HIV co-infected patients is worse than that of pure hepatitis C patients and has a greater impact on the hematopoietic system. It is recommended that patients with conditions of direct antiviral drugs.